维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="GALLEGO MI"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Hepatocytegrowth factor is a lymphangiogenic factor with an indirectmechanism of action显示文摘	CAO R BJ RNDAHL MA GALLEGO MI	2006	Blood2006，107，9：	1
2	Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways 显示文摘	Gallego MI Bierie B Hennighausen L	2003	Oncogene2003，22，52：	1
3	Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action显示文摘	CAO R BJ(E)RNDAHL MA GALLEGO MI	2006	Blood2006，107，9：	1
4	A fast, sensitive and accurate high resolution melting (HRM) technology - based assay to screen for common K - ras mutations 显示文摘	D Kramer A FB Thunnissen A MI Gallegos - Ruiz	2009	Cell Oncol2009，31，：	1
5	Hepatoeyte growth factor is a lymphangiogenic factor with an indirect mechanism of action显示文摘	Cao R BjOrndahl MA Gallego MI	2006	Blood2006，107，9：	1
6	Predictive factors for outcome in a Phase II study of gefitinib in second - line treatment of advanced e- sophageal cancer patients 显示文摘	Janmaat ML Gallegos - Ruiz MI	2006	J Clin Oncol2006，24，10：	1
7	Hepatoeyte growth factor is a lymPhangiogenic factor with an indirect mechanism of action显示文摘	Cao R Bjrndahl MA Gallego MI	2006	Blood2006，107，9：	1
8	Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action 显示文摘	Cao R Bjomdahl MA Gallego MI	2006	Blood2006，107，9：	1
9	Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action显示文摘	Cao R Bj(o)rndahl MA Gallego MI		0，，：	1
10	Membranous glomerulonephritis in a patient with syphilis显示文摘	Mora Mora MT Gallego Dominguez MS Castellano Cervino MI		0，，：	1
11	Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action 显示文摘	Can R Bjorndahl MA Gallego MI Chen S Religa P Hansen A J	2006	Blood2006，107，9：	1
12	Predictive factors for outcome in a phase II study of gefitinib in second - line treatment of advanced esophageal carlcer patients 显示文摘	Janmaat ML Gallegos - Ruiz MI Rodriguez JA	2006	J Clin Oncol2006，24，10：	1
13	Predictive factors for outcome in a phase Ⅱ study of gefitinib in second-line treatment of advanced esophageal cancer patients 显示文摘	Janmaat ML Gallegos - Ruiz MI Rodriguez JA	2006	J Clin Oncol2006，24，10：	1
14	Hepat-ocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action 显示文摘	Cao R Bjorndahl MA Gallego MI	2006	Blood2006，107，9：	1
15	Predictive factors for outcome in a phase II study of gefitinib in second - line treatment of advanced esophageal cancer patients 显示文摘	Janmaat ML Gallegos - Ruiz MI Rodriguez JA	2006	J Clin Oncol2006，24，10：	1
16	Predictive factors for outcome in a phase II study of gefitinib in second - line treatment of advanced esophageal cancer patients 显示文摘	JANMAAT ML GALLEGOS - RUIZ MI RODRIGUEZ JA	2006	J Clin Oncol2006，24，10：	1
17	Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action显示文摘	Cao R Bjorndahl MA Gallego MI	2006	Blood2006，107，9：	1
18	Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action 显示文摘	Cao R Bjorndahl MA Gallego MI	2006	Blood2006，107，9：	1
19	Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways显示文摘	Gallego MI Bierie B Hennighausen L	2003	Oncogene2003，22，52：	1
20	Changes in incidence of malignant melanoma in the last 19 years in a tertiary hospital on the Mediterranean coast 显示文摘	Mareoval J Moreno A Torras A Baumann E Graells J Gallego MI	2008	Actas Dermosifiliogr2008，99，6：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示